223 related articles for article (PubMed ID: 31746426)
1. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
2. MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway.
Wang AQ; Lv M; Xu YH; Xie PM; Dong YY
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9860-9868. PubMed ID: 33090389
[TBL] [Abstract][Full Text] [Related]
3. A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer.
Liu Q; Liu H; Huang X; Fan X; Xiao Z; Yan R; Yao J; An G; Ge Y; Miao J; Liu J
Cancer Gene Ther; 2023 Jan; 30(1):192-208. PubMed ID: 36151333
[TBL] [Abstract][Full Text] [Related]
4. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis.
Wan WN; Zhang YX; Wang XM; Liu YJ; Zhang YQ; Que YH; Zhao WJ
Asian Pac J Cancer Prev; 2014; 15(6):2777-83. PubMed ID: 24761900
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
6. HIF1α-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia.
Nayak A; Roy AD; Rout N; Singh SP; Bhattacharyya A; Roychowdhury A
Biochem Biophys Res Commun; 2020 Mar; 523(4):916-923. PubMed ID: 31959473
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.
Wang XL; Wang S; Wu ZZ; Yang QC; Li H; Xiong HG; Wan SC; Sun ZJ
Int J Med Sci; 2020; 17(11):1598-1609. PubMed ID: 32669963
[TBL] [Abstract][Full Text] [Related]
8. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
9. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
10. ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.
Sun T; Du B; Diao Y; Li X; Chen S; Li Y
BMB Rep; 2019 Jul; 52(7):457-462. PubMed ID: 31186081
[TBL] [Abstract][Full Text] [Related]
11. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
[TBL] [Abstract][Full Text] [Related]
12. Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling.
Wang JH; Yu TT; Li Y; Hao YP; Han L; Xu KY; Xu P
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6055-6063. PubMed ID: 32572920
[TBL] [Abstract][Full Text] [Related]
13. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma.
Fouret R; Laffaire J; Hofman P; Beau-Faller M; Mazieres J; Validire P; Girard P; Camilleri-Bröet S; Vaylet F; Leroy-Ladurie F; Soria JC; Fouret P
Clin Cancer Res; 2012 Oct; 18(20):5606-16. PubMed ID: 22914773
[TBL] [Abstract][Full Text] [Related]
14. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.
Hwang HW; Ha SY; Bang H; Park CK
Cancer Res Treat; 2015 Oct; 47(4):853-61. PubMed ID: 25687855
[TBL] [Abstract][Full Text] [Related]
15. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE.
Guruvaiah P; Chava S; Sun CW; Singh N; Penn CA; Gupta R
Cell Death Dis; 2023 Jul; 14(7):456. PubMed ID: 37479754
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of AAA-domain-containing protein 2 restrains cancer stem cell properties in esophageal squamous cell carcinoma via blockade of the Hedgehog signaling pathway.
Li N; Yu Y; Wang B
Am J Physiol Cell Physiol; 2020 Jul; 319(1):C93-C104. PubMed ID: 31747529
[TBL] [Abstract][Full Text] [Related]
17. [Expression of ATAD2 in different liver lesions and its clinical significance].
Liu F; Zhou X; Ji HH; Li H; Xiang FG
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):339-343. PubMed ID: 28763839
[No Abstract] [Full Text] [Related]
18. MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2.
Dutta M; Das B; Mohapatra D; Behera P; Senapati S; Roychowdhury A
Life Sci; 2022 Jul; 301():120592. PubMed ID: 35504332
[TBL] [Abstract][Full Text] [Related]
19. ATAD2 silencing decreases VEGFA secretion through targeting has-miR-520a to inhibit angiogenesis in colorectal cancer.
Hong S; Chen S; Wang X; Sun D; Yan Z; Tai J; Bi M
Biochem Cell Biol; 2018 Dec; 96(6):761-768. PubMed ID: 29958090
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520f suppresses growth of gastric carcinoma cells by target ATPase family AAA domain-containing protein 2 (ATAD2).
Hong S; Bi M; Chen S; Zhao P; Li B; Sun D; Tai J
Neoplasma; 2016; 63(6):873-879. PubMed ID: 27565325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
